Baricitinib ameliorates behavioral deficits and NLRP3-related neuroinflammation in a ketamine rat model of schizophrenia: Role of JAK2/STAT3 and PI3K/AKT/mTOR signaling.
Baricitinib, a selective JAK1/JAK2 inhibitor with established anti-inflammatory properties, has demonstrated therapeutic efficacy in several autoimmune and inflammatory diseases. This study aimed to investigate the neuroprotective potential of baricitinib in a ketamine-induced rat model of schizophrenia. Specifically,...